AstraZeneca: lung cancer drug reduces risk of death by 32%
(CercleFinance.com) - AstraZeneca said on Tuesday that its immunotherapy Imfinzi reduced the risk of death for patients with Stage III lung cancer by 32%.
A Phase III trial showed Imfinzi (durvalumab) significantly improved overall survival, the second primary endpoint of the trial, compared to standard of care regardless of PD-L1 expression, reducing the risk of death by 32%, the drugmaker said.
The five-year survival rate for this kind of disease has historically been around 15%.
Yesterday the European Commission granted its approval for the marketing of Imfinzi for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 and whose disease has not progressed following chemotherapy and radiation.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
A Phase III trial showed Imfinzi (durvalumab) significantly improved overall survival, the second primary endpoint of the trial, compared to standard of care regardless of PD-L1 expression, reducing the risk of death by 32%, the drugmaker said.
The five-year survival rate for this kind of disease has historically been around 15%.
Yesterday the European Commission granted its approval for the marketing of Imfinzi for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 and whose disease has not progressed following chemotherapy and radiation.
Copyright (c) 2018 CercleFinance.com. All rights reserved.